Aquinox AQX-1125-301-A 12-Week, Randomized, Multi-center

Project: Research project

Description

Aquinox AQX-1125-301-A 12-Week, Randomized, Multi-center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/
StatusFinished
Effective start/end date5/1/174/30/18

Funding

  • AQUINOX PHARMACEUTICALS, INC.

Fingerprint

Interstitial Cystitis
compound A 12
Placebos
Safety
4-(4-(aminomethyl)-7a-methyl-1-methylideneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexan-1-ol